Search Results - therapeuticarea+%3e+psychiatry%2fmental+health

16 Results

Sort By:

Discovery of Novel SHT (SHT6) Compounds for the Treatment of Central Nervous System-related Diseases

This technology includes novel compounds which can be expected to selectively target the 5HT6 receptor, which is implicated in CNS-related diseases. In particular 5HT6 antagonism has been implicated in cognitive impairment, AD/PD and drug abuse/alcohol abuse related disorders. 5HT6 compounds have also shown to reduce appetite and induce weight loss....

Published: 8/12/2024 | Inventor(s): Malliga Iyer, Kyu Kim

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Computational models/software, ResearchProducts > Human Cell Lines, TherapeuticArea > Endocrinology, TherapeuticArea > Metabolic Disease, TherapeuticArea > Neurology, TherapeuticArea > Psychiatry/Mental Health

A Mood-Machine-Interface as an Intervention for Emotional Self-Regulation in Real-Time

This technology relates to a closed-loop controller that is being developed as a phone app for emotional self-regulation in real-time. There is a significant association between emotion dysregulation and symptoms of depression, anxiety, eating pathology, and substance abuse, affecting millions worldwide. Consisting of a closed-loop controller that adjusts...

Published: 7/25/2024 | Inventor(s): Argyris Stringaris, Hanna Keren

Keywords(s): INTERVENTION, MEASURE, Mood-Machine-Interface, OUTCOME, VNXXXX, WMXXXX, XDXXXX, XHXXXX, XJXXXX

Category(s): ResearchProducts > Computational models/software, Application > Consumer Products, Application > Non-Medical Devices, TherapeuticArea > Psychiatry/Mental Health, Application > Medical Devices, Application > Software / Apps, ResearchProducts > Research Equipment

Radioligand for imaging brain PDE4 subtype D receptors with positron emission tomography

The technology relates to the first radioligands that can be used to image and quantify the enzyme phosphodiesterase subtype D (PDE4D). The PDE4D proteins have a role in carrying out signal transduction pathways in several cell types and is thought to be the key target of various antidepressants. Current work with imaging the radioligands in monkey...

Published: 7/25/2024 | Inventor(s): Sanjay Telu, Robert Innis, Robert Nugent, Mark Gurney, Xuesheng Mo, Victor Pike

Keywords(s): brain, D, Emission, IMAGING, PDE4, Positron, Radioligand, RECEPTORS, Subtype, tomography, VEXXXX, VNXXXX, WBXXXX, WIXXXX, XCXXXX, XFXXXX

Category(s): Application > Diagnostics, Application > Research Materials, Application > Non-Medical Devices, TherapeuticArea > Neurology, TherapeuticArea > Psychiatry/Mental Health, Application > Medical Devices, Application > Software / Apps

Novel NMDA ligands that are specific and selective to the NR2B subunits based on the derivatives of 7-methoxy-3-(4-phenylbutyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-ol

This invention includes the design and synthesis of ligands that bind selectively and specifically to the NR2B subunit of the NMDA receptor. The NMDA receptor is thought to play a role in the pathophysiology of psychiatric disorders, including depression, stroke, drug addiction, and neuropathic pain. Existing ligands to the NMDA receptor are widely...

Published: 7/25/2024 | Inventor(s): Victor Pike, Lisheng Cai

Keywords(s): 3, 4, 5-tetrahydro-1H-benzo[d]azepin-1-ol, 7-methoxy-3-4-phenylbutyl-2, Based, Derivatives, LIGANDS, NR2B, VNXXXX, WIXXXX

Category(s): Application > Research Materials, TherapeuticArea > Psychiatry/Mental Health

Diagnosis and Treatment of Pediatric Acute Neurologic Syndrome with Antineuronal Antibodies

The invention is a panel of five tests of patient sera for immune responses that may attack the brain and lead to the characteristic symptoms of pediatric acute neurologic syndrome (PANS). PANS is a condition defined by a sudden onset of obsessive-compulsive symptoms, eating restrictions, and other cognitive and/or behavioral symptoms. Currently, the...

Published: 7/25/2024 | Inventor(s): Susan Swedo, Christine Kirvan, Madelein Cunningham

Keywords(s): ACUTE, antibodies, Antineuronal, Diagnosis, Listed LPM Greene as of 4/15/2015, Neurologic, pediatric, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Syndrome, treatment, VEXXXX, VNXXXX, WBXXXX, WIXXXX, XAXXXX, XCXXXX

Category(s): TherapeuticArea > Psychiatry/Mental Health, TherapeuticArea > Neurology, TherapeuticArea > Immunology, Application > Research Materials, Application > Diagnostics, ResearchProducts > Antibodies

Imaging Inflammation using PET Radioligands that Target Translocator Protein 18?kDa with High Affinity Regardless of Genotype

This technology includes a group of radioligands that label inflammatory cells specifically, accurately, and across different genotypes and can be detected using Positron Emission Tomography (PET). The radioligands target the Translocator protein 18 kDa (TSPO) receptor which is present on the outer mitochondrial membrane and is involved in the production...

Published: 7/25/2024 | Inventor(s): Chad Brouwer, Victor Pike

Keywords(s): 18kDa, Emission, Genotype, Human, Listed LPM Fenn as of 4/15/2015, Positron, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Quantifying/imaging, Radioligands, Regardless, tomography, TSPO, VEXXXX, VNXXXX, WBXXXX, WIXXXX, XCXXXX, XFXXXX

Category(s): Application > Research Materials, Application > Diagnostics, TherapeuticArea > Neurology, Application > Medical Devices, Application > Non-Medical Devices, Application > Software / Apps, TherapeuticArea > Psychiatry/Mental Health

Imaging Inflammation using PET Radioligands that Target Translocator Protein 18?kDa with High Affinity Regardless of Genotype

Published: 7/25/2024 | Inventor(s): Robert Innis, Federico Da Settimo, Giorgio Stefancich, Sabrina Taliani, Sabrina Castellano, Claudia Martini, Yi Zhang, Victor Pike

Keywords(s): 18kDa, Emission, Genotype, Human, Listed LPM Fenn as of 4/15/2015, NA1XXX, Positron, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Quantifying/imaging, Radioligands, Regardless, tomography, TSPO, VEXXXX, VNXXXX, WBXXXX, WIXXXX, XCXXXX, XFXXXX

Category(s): TherapeuticArea > Psychiatry/Mental Health, Application > Non-Medical Devices, TherapeuticArea > Neurology, Application > Software / Apps, Application > Diagnostics, Application > Medical Devices, Application > Research Materials

Murine Model of Niemann-Pick Disease Type C

This technology includes a transgenic mouse model of Niemann-Pick Disease Type C (NPC), which is a rare neurodegenerative disorder, characterized by intracellular accumulation of cholesterol and gangliosides. The mouse strain, Tg(Npcl), expresses wild-type NPC1 gene under the control of the prion promoter. When combined with the NPC deficient mouse...

Published: 7/25/2024 | Inventor(s): Stacie Loftus, William ("Bill") Pavan

Keywords(s): C, Disease, Listed LPM Maddox as of 4/15/2015, Model, Murine, NIEMANN-PICK, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RXXXXX, VEXXXX, VHXXXX, VNXXXX, VPXXXX, WIXXXX, WKXXXX, XEXXXX

Category(s): TherapeuticArea > Infectious Disease, TherapeuticArea > Psychiatry/Mental Health, Application > Therapeutics, TherapeuticArea > Endocrinology, TherapeuticArea > Dental, TherapeuticArea > Oncology, TherapeuticArea > Cardiology, TherapeuticArea > Neurology, Application > Research Materials, TherapeuticArea > Ophthalmology

Use of the Ketamine Metabolite (R,6R)-hydroxynorketamine in Depression

This technology includes the identification and use of a ketamine metabolite, (2R,6R)-2-amino-2-(2-chlorophenyl)-6-hydroxycyclohexanone (HNK), for the treatment of depression. Ketamine is an NMDA receptor antagonist that exerts a rapid and sustained antidepressant and anti-suicidal effect. However, even low doses of ketamine has addictive and psychomimetic...

Published: 7/25/2024 | Inventor(s): Todd Gould, Irving Wainer, Carlos Zarate, Ruin Moaddel, Patrick Morris, Panos Zanos, Craig Thomas

Keywords(s): 2R, 6R-hydroxynorketamine, depression, Ketamine, METABOLITE, VEXXXX, VNXXXX, WIXXXX, WKXXXX

Category(s): TherapeuticArea > Neurology, TherapeuticArea > Psychiatry/Mental Health, Application > Therapeutics, Application > Research Materials

A Novel Reagent for Labeling PET Tracers at Trifluoromethyl Groups

The molecular imaging technique of positron emission tomography (PET) is an increasingly important tool in biomedical research and in drug discovery and development. Many small molecule drugs and potential PET radiotracers carry trifluoromethyl (CF3) groups. Because CF3 groups are generally considered to be metabolically stable, there is a strong interest...

Published: 7/25/2024 | Inventor(s): Mohammad Haskali, Victor Pike

Keywords(s): :, [11C]Fluoroalkanes, Added, AGENT, LABELING, Method, No-Carrier, PET, Producing, Radiotracers, VAXXXX, VCXXXX, VDXXXX, VEXXXX, VNXXXX, WBXXXX, WIXXXX, XDXXXX, XFXXXX, YAXXXX, YBXXXX, YFXXXX

Category(s): Collaboration Sought > Collaboration, Application > Diagnostics, Application > Research Materials, TherapeuticArea > Oncology, TherapeuticArea > Cardiology, Application > Non-Medical Devices, TherapeuticArea > Geriatrics, Application > Software / Apps, TherapeuticArea > Psychiatry/Mental Health, TherapeuticArea > Neurology, Application > Medical Devices, TherapeuticArea > Immunology

1 2